1-10 of 10
Serengulam V. Govindan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo

Available to Purchase
Ian Nessler, Baron Rubahamya, Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Nalini Sathyanarayan, Jennifer Donnell, Serengulam V. Govindan, Greg M. Thurber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (3): 343–353.
https://doi.org/10.1158/1535-7163.MCT-23-0437
Published: 04 March 2024
View articletitled, Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo
Open the PDF for Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Open Access
Anna Kopp, Scott Hofsess, Thomas M. Cardillo, Serengulam V. Govindan, Jennifer Donnell, Greg M. Thurber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (1): 102–111.
https://doi.org/10.1158/1535-7163.MCT-22-0375
Published: 03 January 2023
View articletitled, Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
Open the PDF for Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release in another window
Includes: Supplementary data
Journal Articles

Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter

Available to Purchase
David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 237.
https://doi.org/10.1158/1535-7163.MCT-21-0212
Published: 07 January 2022
View articletitled, Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter
Open the PDF for Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter in another window
Journal Articles

Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)

Free
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, Jennifer Donnell, Jing Xia, Edmund A. Rossi, Chien-Hsing Chang, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1): 196–203.
https://doi.org/10.1158/1535-7163.MCT-17-0442
Published: 01 January 2018
View articletitled, Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)
Open the PDF for Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130) in another window
Includes: Supplementary data
Journal Articles

IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma

Free
Thomas M. Cardillo, Serengulam V. Govindan, Maria B. Zalath, Diane L. Rossi, Yang Wang, Chien-Hsing Chang, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (1): 150–160.
https://doi.org/10.1158/1535-7163.MCT-17-0354
Published: 01 January 2018
View articletitled, IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma
Open the PDF for IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma in another window
Includes: Supplementary data
Journal Articles

Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)

Free
Thomas M. Cardillo, Serengulam V. Govindan, Maria Zalath, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C166.
https://doi.org/10.1158/1535-7163.TARG-15-C166
Published: 01 December 2015
View articletitled, Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)
Journal Articles

Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

Free
Alexander N. Starodub, Allyson J. Ocean, Michael J. Guarino, Ellen Chuang, Manish A. Shah, Scott Tagawa, Vincent J. Picozzi, Sajeve S. Thomas, Pius P. Maliakal, William A. Wegener, Robert M. Sharkey, Serengulam V. Govindan, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C67.
https://doi.org/10.1158/1535-7163.TARG-13-C67
Published: 01 November 2013
View articletitled, Abstract C67: Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.
Journal Articles

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers

Free
Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 968–978.
https://doi.org/10.1158/1535-7163.MCT-12-1170
Published: 09 June 2013
View articletitled, Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Open the PDF for Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers in another window
Includes: Supplementary data
Journal Articles

Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies

Free
Robert M. Sharkey, Serengulam V. Govindan, Thomas M. Cardillo, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (1): 224–234.
https://doi.org/10.1158/1535-7163.MCT-11-0632
Published: 09 January 2012
View articletitled, Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies
Open the PDF for Epratuzumab–SN-38: A New Antibody–Drug Conjugate for the Therapy of Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

Free
Robert M. Sharkey, Habibe Karacay, Serengulam V. Govindan, David M. Goldenberg
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (6): 1072–1081.
https://doi.org/10.1158/1535-7163.MCT-11-0115
Published: 08 June 2011
View articletitled, Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models
Open the PDF for Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models in another window
Includes: Supplementary data